Wegovy（司美格鲁肽）是首个用于治疗肥胖的口服胰高血糖素样肽-1（GLP-1）受体激动剂。FDA的批准意味着这一新型药物将在2026年1月初上市，预计将为超重或肥胖患者提供有效的治疗方案。Wegovy不仅能帮助患者减轻体重，还能降低心血管疾病的风险，这无疑是肥胖治疗领域的一次重大突破。

从减重降糖到护心救肝，GLP-1药物的跨界潜力正持续被挖掘。随着全球市场的逐步渗透与临床研究的深入，司美格鲁肽有望进一步改写MASH的治疗格局，甚至推动整个肝病治疗领域进入“代谢调节”的全新阶段。未来，如何应对竞争压力、解决产能瓶颈，将是诺和诺德能否持续领跑MASH治疗市场的关键所在。 返回搜狐，查看更多 ...

In the studies the company submitted to the FDA, people who took the daily Wegovy pill lost about the same amount of ...

11 月，诺和诺德与礼来制药根据与特朗普政府达成的协议约定，若其减重口服药获批，将为美国联邦医保（Medicare）、医疗救助（Medicaid）患者及无保险覆盖的自费用户，提供每月 149 美元的起始剂量定价。

诺和诺德开发的肥胖症治疗药“Wegovy”2021年在美国获批，由于只要自己注射即可抑制食欲，作为简单的减肥药，正在掀起一股跨越年代的热潮。美国的国民有40%属于肥胖者，新药被期待可以解决美国的这一国民病。不过，新的问题也随之而来…… ...

The Wegovy pill is one of two oral GLP-1 drugs expected to hit the market in the next few months; the other, from Lilly, is called orforglipron – until it receives a brand name – and is expected to be ...

Investing.com - 诺和诺德公司 (NYSE:NVO)股价在周一盘后交易中跃升近8%，此前美国食品药品监督管理局 (FDA)批准了该公司的Wegovy片剂，这是首款用于体重管理的口服GLP-1受体激动剂。

Novo Nordisk’s oral Wegovy gets FDA approval, but rising costs and competition threaten profits. Learn why analysts rate NVO ...

Demand for weight loss drugs has soared over the last year, to the point that semaglutide — better known by the brand names Ozempic and Wegovy — has been in short supply at pharmacies nationwide.

These days, it's almost impossible to get away from Ozempic. The prescription drug has been all over the news in the past couple of years — but the name Ozempic has become something of a shorthand, ...

Some of Novo Nordisk’s popular weight loss drug Wegovy is back in stock in the U.S. after months of limited supplies, according to an update on the Food and Drug Administration’s website, though ...

At the end of the summer, Steve Johnson became one of the legions of Americans curious about a new weight-loss drug called Wegovy (semaglutide). The medical device salesperson had been fasting ...